Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6410
    -0.0015 (-0.24%)
     

  • OIL

    82.28
    -0.45 (-0.54%)
     

  • GOLD

    2,395.60
    -2.40 (-0.10%)
     

  • Bitcoin AUD

    100,879.12
    +4,595.70 (+4.77%)
     

  • CMC Crypto 200

    1,329.25
    +16.62 (+1.28%)
     

  • AUD/EUR

    0.6017
    -0.0014 (-0.24%)
     

  • AUD/NZD

    1.0889
    +0.0014 (+0.13%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,833.13
    -43.92 (-0.56%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,724.38
    -113.02 (-0.63%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Repligen Corporation to Present at Barclays Global Healthcare Conference

Repligen Corporation
·1-min read

WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.

A live webcast of the discussion will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com